BRIEF-Boehringer Ingelheim says jardiance becomes first type 2 diabetes medicine in EU to include cardiovascular death reduction data in label

* Boehringer ingelheim- jardiance (empagliflozin) becomes

first type 2 diabetes medicine in eu to include cardiovascular

death reduction data in label

Read more